News - Novartis, Pharmaceutical

Filter

Current filters:

NovartisPharmaceutical

Popular Filters

1 to 25 of 340 results

Novartis 2nd-qtr sales and net profit up but miss analysts’ forecasts

Novartis 2nd-qtr sales and net profit up but miss analysts’ forecasts

17-07-2014

Switzerland’s Novartis – now the world’s largest pharmaceutical company by sales - this morning…

AlconFinancialNovartisPharmaceuticalSandoz

Novartis collaborates with Banner Alzheimer's Inst on AD prevention study

Novartis collaborates with Banner Alzheimer's Inst on AD prevention study

15-07-2014

Swiss pharma major Novartis has set up a collaboration with US not-for-profit group the Banner Alzheimer's…

Active immunotherapyAlzheimer's diseaseEuropeNeurologicalNovartisNovartis PharmaceuticalsPharmaceuticalResearchUSA

Novartis’ secukinumab significantly more effective in psoriasis than NICE-recommended equivalent

Novartis’ secukinumab significantly more effective in psoriasis than NICE-recommended equivalent

10-07-2014

Data published in the New England Journal of Medicine has shown secukinumab to be more effective at treating…

DermatologicalsetanerceptNovartisPharmaceuticalPsoriasisResearchsecukinumabUSA

Novartis receives fifth Breakthrough Therapy designation with CTL019 for leukemia

Novartis receives fifth Breakthrough Therapy designation with CTL019 for leukemia

08-07-2014

Swiss drug major Novartis has been granted Breakthrough Therapy designation for its leukemia treatment…

CancerCTL019LeukemiaNovartisOncologyPharmaceuticalRefractory acute lymphoblastic leukemiaRegulationUSA

Novartis takes action as former employee is arrested in Japan

Novartis takes action as former employee is arrested in Japan

02-07-2014

Swiss drug major Novartis (NOVN: VX) said yesterday that Novartis Pharma K.K. (NPKK) understands that…

JapanLegalNovartisPharmaceutical

UK’s NICE draft guidance backs Novartis’ Glivec for GISTs

UK’s NICE draft guidance backs Novartis’ Glivec for GISTs

27-06-2014

UK health care watchdog the National Institute for Health and Care Excellence (NICE) has issued new draft…

GlivecNovartisOncologyPharmaceuticalPricingRegulationUK

Novartis subject to Italian investigation over alleged vaccine fraud

Novartis subject to Italian investigation over alleged vaccine fraud

23-06-2014

Swiss drug maker Novartis is the subject of a new investigation by Italian authorities. The company’s…

Health Medical PharmaInfluenzaItalyLegalMedicineNovartisPharmaceuticalPharmacologyVaccines

Novartis outlines aims to be more profitable and increasingly focused

Novartis outlines aims to be more profitable and increasingly focused

19-06-2014

Swiss drug major Novartis has set out its new focused portfolio at the first Meet Novartis Management…

EuropeManagementNovartisOncologyOphthalmicsPharmaceutical

FDA licenses Novartis facility to produce cell-culture influenza vaccines

FDA licenses Novartis facility to produce cell-culture influenza vaccines

16-06-2014

The US Food and Drug Administration has licensed Swiss pharma major Novartis’ manufacturing facility…

FlucelvaxNovartisPharmaceuticalProductionRegulationUSAVaccines

Italian legislation undermines EU regulatory framework by endorsing off-label drug use for economic reasons

Italian legislation undermines EU regulatory framework by endorsing off-label drug use for economic reasons

11-06-2014

The European Federation of Pharmaceutical Industries and Associations says it is concerned about a decision…

AvastinEuropeFinancialItalyNovartisOphthalmicsPharmaceuticalRegulationRoche

Wider use of Novartis’ Gilenya approved in Europe

Wider use of Novartis’ Gilenya approved in Europe

09-06-2014

The European Commission has endorsed the recent Committee for Medicinal Products for Human Use (CHMP)…

EuropeGilenyaNeurologicalNovartisPharmaceuticalRegulation

Avastin could save the USA $29 billion if used instead of Lucentis

Avastin could save the USA $29 billion if used instead of Lucentis

04-06-2014

Using Avastin (bevacizumab) from Swiss drug major Roche instead of Lucentis (ranibizumab) from fellow…

AvastinBevacizumabFinancialLucentisNovartisOphthalmicsPharmaceuticalRocheUSA

Novartis’ Glivec could lose half patient population in China to generics

Novartis’ Glivec could lose half patient population in China to generics

03-06-2014

Hematologists in China estimate that Glivec (imatinib) from Swiss drug major Novartis will lose nearly…

Blast phase CMLChemistryChinaChronic phase CMLGlivecHealth Medical PharmaHematologyMajorMarkets & MarketingNovartisPharmaceutical

EMA/CHMP again rejects Novartis’ serelaxin for AHF

26-05-2014

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has for a second…

Cardio-vascularEuropeNovartisPharmaceuticalReasanzRegulationserelaxin

EMA/CHMP backs Alcon’s Simbrinza for glaucoma

25-05-2014

Swiss drug major Novartis’ eye care division Alcon says that the European Medicines Agency’s Committee…

AlconEuropeNovartisOphthalmicsPharmaceuticalRegulationSimbrinza

Servier inks oncology collaboration with Novartis

20-05-2014

French independent drugmaker Laboratories Servier has signed a strategic global collaboration agreement…

LicensingNovartisOncologyPharmaceuticalServier

US FDA stalls approval of Novartis acute heart failure drug serelaxin, issuing a CRL

US FDA stalls approval of Novartis acute heart failure drug serelaxin, issuing a CRL

16-05-2014

The US Food and Drug Administration has issued a Complete Response Letter regarding the Biologics License…

Cardio-vascularNovartisPharmaceuticalReasanzRegulationserelaxinUSA

Novartis presents real world data for Lucentis

Novartis presents real world data for Lucentis

09-05-2014

Swiss drug major Novartis has reported data on the eye drug Lucentis (ranibizumab) at the 2014 Association…

AMDEuropeHealthLucentisMajorMedicineNovartisOphthalmicsOphthalmologyPharmaceuticalResearch

Novartis’ Signifor LAR shows superior efficacy in certain acromegaly patients

Novartis’ Signifor LAR shows superior efficacy in certain acromegaly patients

06-05-2014

Swiss drug major Novartis has presented positive results from a pivotal Phase III trial of investigational…

NovartisPharmaceuticalRare diseasesResearchSignifor

AAN 2014: Novartis’ MS drug Gilenya slows brain volume loss

30-04-2014

Data from Swiss drug major Novartis has shown that more patients with relapsing multiple sclerosis treated…

EuropeGilenyaHealthHealth Medical PharmaMedicineMSMultiple sclerosisNeurologicalNovartisPharmaceuticalResearch

Novartis’ Ultibro Breezhaler shows superior efficacy over Seretide in COPD

Novartis’ Ultibro Breezhaler shows superior efficacy over Seretide in COPD

30-04-2014

Swiss drug major Novartis today announced positive first results from the Phase III head-to-head LANTERN…

COPDEuropeHealth Medical PharmaMedicineNovartisPharmaceuticalPulmonologyResearchRespiratory and PulmonaryRespiratory therapySeretideUltibro Breezhaler

1 to 25 of 340 results

Back to top